Serum amyloid P component-DNA complexes are decreased in systemic lupus erythematosus. Inverse association with anti-dsDNA antibodies

Journal of Rheumatology

Volumn 35, Issue 4, 2008, Pages 625-630

  Voss, Anne ^a   Holm Nielsen, Ellen ^b   Svehag, Sven Erik ^b   Junker, Peter ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Anti double stranded DNA complexes; Immunology; Serum amyloid P component; Systemic lupus erythematosus

Indexed keywords

AMYLOID P COMPONENT; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; COHORT ANALYSIS; CONTROL GROUP; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GROUPS BY AGE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCANDINAVIA; SEROLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, ANTINUCLEAR; BLOOD SEDIMENTATION; COMPLEMENT C3D; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SERUM AMYLOID P-COMPONENT;

EID: 41849096730     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Andrade F, Casciola-Rosen L, Rosen A. Apoptosis in systemic lupus erythematosus. Clinical implications. Rheum Dis Clin North Am 2000;26:215-27.
2. Hahn BH. Antibodies to DNA. N Engl J Med 1998;338:1359-68.
3. Gaipl US, Brunner J, Beyer TD, Voll RE, Kalden JR, Herrmann M. Disposal of dying cells: a balancing act between infection and autoimmunity. Arthritis Rheum 2003;48:6-11.
4. Walport MJ. Lupus, DNase and defective disposal of cellular debris. Nat Genet 2000;25:135-6.
5. Munoz LE, Gaipl US, Franz S, et al. SLE - a disease of clearance deficiency? Rheumatology Oxford 2005;44:1101-7.
6. Qiao B, Wu J, Chu YW, et al. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology Oxford 2005;44:1108-14.
7. Bickerstaff MCM, Botto M, Hutchinson WL, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nature Med 1999;5:694-7.
8. Gillmore JD, Hutchinson WL, Herbert J, et al. Autoimmunity and glomerulonephritis in mice with targeted deletion of the serum amyloid P component gene: SAP deficiency or strain combination? Immunology 2004;112:255-64.
9. Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG. Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocyte-derived macrophages. Arthritis Rheum 2003;48:248-54.
10. Familian A, Zwart B, Huisman H-G, et al. Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 2001;167:647-54.
11. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fc-gamma receptors. J Autoimmun 2002;19:147-54.
12. Juul Sorensen I, Holm Nielsen E, Schroder H, Voss A, Horvath L, Svehag S-E. Complexes of serum amyloid P component and DNA in serum from healthy individuals and systemic lupus erythematosus patients. J Clin Immunol 2000;20:408-15.
13. Sen J-W, Recke C, Rahbek L, Skogstrand K, Heegaard N-H. Structural, quantitative and functional comparison of amyloid P component in sera from patients with systemic lupus erythematosus and healthy donors. Scand J Immunol 2002;56:645-51.
14. Voss A, Green A, Junker P. Systemic lupus erythematosus in Denmark: Clinical and epidemiological characterization of a county-based cohort. Scand J Rheumatol 1998;27:98-105.
15. Fries JF, Holman HR. Systemic lupus erythematosus: a clinical analysis. In: Smith LH Jr, editor. Major problems in internal medicine. Philadelphia: WB Saunders Co.; 1975:1-199.
16. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
18. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
19. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
20. Gladman DD, Urowitz MB, Goldsmith CH, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:809-13.
21. Juul Sorensen I, Andersen O, Holm Nielsen E, Svehag S-E. Multiple isoforms of the human pentraxin serum amyloid p component. Int Arch Allergy Immunol 1995;106:25-31.
22. Napirei M, Karsunky H, Zevnik B, Stephan H, Mannherz HG, Moray T. Features of systemic lupus erythematosus in Dnase 1-deficient mice. Nat Genet 2000;25,177-81.
23. Amoura Z, Chabre H, Bach J-F, Koutouzov S. Antinucleosome antibodies and systemic lupus erythematosus. Adv Nephrol Necker Hosp 1997;26:303-16.
24. Bijl M, Regal RR, Horst G, Limburg PC, Kallenberg CG. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis 2006;65:57-63.
25. Bijl M, Bootsma H, Van Der Geld Y, Limburg PC, Kallenberg CG, van Rijswijk MH. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004;63:831-5.
26. Zandman-Goddard G, Blank M, Langevitz P, et al. Anti-serum amyloid component P antibodies in patients with systemic lupus erythematosus correlate with disease activity. Ann Rheum Dis 2005;64:1698-702.